Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Shares Outstanding (Diluted Average) (2021 - 2025)

Historic Shares Outstanding (Diluted Average) for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $98.8 million.

  • ARS Pharmaceuticals' Shares Outstanding (Diluted Average) rose 182.96% to $98.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.8 million, marking a year-over-year increase of 182.96%. This contributed to the annual value of $102.4 million for FY2024, which is 753.61% up from last year.
  • As of Q3 2025, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $98.8 million, which was up 182.96% from $98.4 million recorded in Q2 2025.
  • ARS Pharmaceuticals' Shares Outstanding (Diluted Average)'s 5-year high stood at $102.4 million during Q4 2024, with a 5-year trough of $28.9 million in Q4 2021.
  • Over the past 5 years, ARS Pharmaceuticals' median Shares Outstanding (Diluted Average) value was $95.2 million (recorded in 2023), while the average stood at $74.3 million.
  • In the last 5 years, ARS Pharmaceuticals' Shares Outstanding (Diluted Average) tumbled by 1213.19% in 2022 and then soared by 21076.65% in 2023.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $28.9 million in 2021, then surged by 38.39% to $40.0 million in 2022, then skyrocketed by 138.3% to $95.2 million in 2023, then grew by 7.54% to $102.4 million in 2024, then dropped by 3.5% to $98.8 million in 2025.
  • Its last three reported values are $98.8 million in Q3 2025, $98.4 million for Q2 2025, and $98.1 million during Q1 2025.